Skip to content
ES
MARKETS / NASDAQ / DERM
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Journey Medical Corp. DERM

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$61.2M
▲ 11.1% YoY
$-11.4M
In brief

What this company does

We are a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration ("FDA") approved prescription pharmaceutical products for the treatment of dermatological conditions. Our current product portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. We are a controlled subsidiary of Fortress Biotech, Inc. ("Fortress" or "Parent"). Journey Medical Corporation was incorporated in Delaware in 2014. On November 1, 2024, the FDA approved Emrosi for the treatment of inflammatory lesions of rosacea in adults. As of March 18, 2026, we had 58 employees, all of whom are full-time employees.

Written from the business description in Journey Medical Corp's annual report to the U.S. Securities and Exchange Commission, filed 26 March 2026. Every sentence was checked against that document before publication.

Growth
USD 61.2M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 61.2 · Net income -11.4
25.0M50.0M-20.0M-40.0M202020212022202320242025
Compound annual growth
−4.8%
+6.6%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +6.6% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−19 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -13.3% · Net -18.7%
5%10%15%-20%-40%-60%202020212022202320242025
ROE
FY2025 · ROE -44.0%
20%40%-50%-100%-150%202020212022202320242025
Gross margin65.8%
Operating margin-13.3%
Net margin-18.7%
Return on assets-13.1%
EBITDA—

Each USD of equity lost 44 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2024 · FCF -24.1
-20M202020212022202320242025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 94.6M
EquityUSD 31.9M
CashUSD 24.1M
Gross debtUSD 25.3M
Net debtUSD 1.2M
Current ratio1.79×

Net debt stands at 4% of equity.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020
Revenue $B0.10.10.10.10.10.0
Operating income $B−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B····−0.00.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.00.0
Free cash flow $B·−0.00.0−0.0··
EPS, diluted $−0.47−0.72−0.21−1.69−4.320.49
Dividend / sh $······
Payout %······
ROE %−44.0−72.6−20.6−100.4−168.151.3

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 24 reconciliationsAUDITED

Reconciled in 6 of 19 fiscal years. 65 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image